sacm1la Antibody

What is SACM1L and what cellular functions does it perform?

SACM1L (SAC1 suppressor of actin mutations 1-like) is a phosphoinositide phosphatase that primarily catalyzes the hydrolysis of phosphatidylinositol 4-phosphate (PtdIns(4)P). It also demonstrates catalytic activity toward phosphatidylinositol 3-phosphate (PtdIns(3)P) and exhibits low activity against phosphatidylinositol-3,5-bisphosphate (PtdIns(3,5)P2). SACM1L shows particularly robust phosphatase activity when binding PtdIns(4)P in a 'cis' configuration within cellular environments, with significantly reduced activity observed during 'trans' configuration binding. Notably, its PtdIns(4)P phosphatase activity (when binding in 'trans' configuration) increases substantially in the presence of PLEKHA3, suggesting regulatory interactions within phosphoinositide signaling pathways .

What applications are SACM1L antibodies suitable for?

SACM1L antibodies have been validated for multiple research applications with specific performance parameters:

It is strongly recommended that researchers titrate these antibodies in their specific testing systems to achieve optimal results, as performance can be sample-dependent .

What species reactivity has been confirmed for SACM1L antibodies?

Commercial SACM1L antibodies have demonstrated confirmed reactivity with human, mouse, and rat samples. This cross-species reactivity makes these antibodies valuable tools for comparative studies across mammalian models. Published literature has documented successful application in all three species, providing researchers with flexibility when designing experiments involving multiple model organisms .

What is the expected molecular weight of SACM1L in Western blot applications?

When performing Western blot analysis, researchers should expect to observe SACM1L at 60-67 kDa, which aligns with its calculated molecular weight of 67 kDa (587 amino acids). This range accounts for potential post-translational modifications or slight variations in gel migration patterns. Confirming the appropriate molecular weight band is crucial for validating antibody specificity, particularly when working with novel tissue samples or cell lines .

How can researchers optimize antigen retrieval for SACM1L immunohistochemistry?

For optimal SACM1L detection in fixed tissues, researchers should implement a dual-approach antigen retrieval strategy. Primary recommendation is TE buffer at pH 9.0, which effectively unmasks SACM1L epitopes while preserving tissue morphology. Alternatively, citrate buffer at pH 6.0 can be employed when alkaline conditions are unsuitable for specific co-staining protocols. In challenging tissue samples with high fixation variability, a systematic comparison of both methods is advised, with quantitative assessment of signal-to-noise ratios to determine optimal conditions. Extended retrieval times (15-20 minutes) may be necessary for heavily fixed specimens, but researchers should monitor for potential tissue degradation .

What controls are essential for validating SACM1L antibody specificity in experimental systems?

Rigorous validation of SACM1L antibody specificity requires implementation of multiple control strategies:

• Genetic depletion controls: SACM1L siRNA/shRNA knockdown or CRISPR-Cas9 mediated knockout samples provide definitive negative controls, as demonstrated in published research where SACM1L antibody signal was absent in depleted samples.

• Peptide competition assays: Pre-incubation of the antibody with the immunizing peptide should abolish specific signal in all applications.

• Cross-validation: Using two different SACM1L antibodies (preferably targeting different epitopes) helps confirm specific detection patterns.

• Species-appropriate negative controls: Sample types documented to lack SACM1L expression serve as valuable negative controls.

This multi-faceted validation approach ensures experimental rigor and reproducibility in SACM1L research .

How can researchers implement multiplexed detection protocols involving SACM1L antibody?

Successful multiplexed detection strategies for SACM1L require careful consideration of antibody compatibility, fluorophore selection, and detection methodology. For immunofluorescence applications, researchers should:

• Select primary antibodies raised in different host species (e.g., rabbit anti-SACM1L with mouse antibodies against other targets).

• When same-species antibodies cannot be avoided, implement sequential staining with isotype-specific secondary antibodies. For example:

• Include extensive washing steps between applications of different antibody pairs to minimize cross-reactivity.

• Validate multiplexed protocols with single-staining controls to confirm absence of fluorophore bleed-through and antibody cross-reactivity .

What methodological approaches can address non-specific binding in SACM1L immunodetection?

Non-specific binding in SACM1L immunodetection can be methodically addressed through several evidence-based optimization strategies:

• Blocking optimization: Systematic comparison of blocking agents (BSA, normal serum, commercial blockers) at varying concentrations (1-10%) and incubation times (30 minutes to overnight) to identify optimal signal-to-noise ratio.

• Antibody dilution titration: Performing serial dilutions beyond manufacturer's recommendations (e.g., testing 1:100 to 1:5000 for WB) to identify the highest dilution producing specific signal.

• Detergent modification: Adjusting Tween-20 concentration in wash buffers (0.05-0.3%) or introducing alternative detergents like Triton X-100 for membrane permeabilization applications.

• Incubation temperature optimization: Comparative analysis of room temperature versus 4°C antibody incubations, with extended times for lower temperatures to maintain binding kinetics.

For particularly challenging samples, pre-adsorption of secondary antibodies against tissue from the experimental species can significantly reduce non-specific interactions .

How can researchers address weak or absent SACM1L signal in Western blot applications?

When encountering weak or absent SACM1L signal in Western blot applications, researchers should implement a systematic troubleshooting approach:

• Sample preparation optimization: Ensure complete protein extraction using specialized lysis buffers containing phosphatase inhibitors, as SACM1L is a phosphoinositide phosphatase that may be sensitive to extraction conditions.

• Loading concentration adjustment: Increase sample loading to 50-75 μg of total protein, as SACM1L may be expressed at lower levels in certain tissues or cell types.

• Transfer efficiency verification: Use reversible total protein stains (Ponceau S) to confirm successful transfer, particularly for proteins in SACM1L's molecular weight range (60-67 kDa).

• Antibody incubation protocol modification:

  • Extend primary antibody incubation to overnight at 4°C

  • Reduce antibody dilution to 1:500 (from recommended 1:500-1:2000 range)

  • Add 5% BSA to antibody diluent to enhance specific binding

• Detection system sensitivity evaluation: Compare chemiluminescent reagents of differing sensitivities or consider fluorescent secondary antibodies for enhanced detection limits .

What strategies can resolve high background in SACM1L immunofluorescence applications?

High background in SACM1L immunofluorescence can be methodically addressed through these evidence-based optimization approaches:

• Fixation protocol refinement: Compare paraformaldehyde (4%), methanol, and acetone fixation protocols to identify optimal epitope preservation with minimal autofluorescence.

• Autofluorescence reduction: Implement tissue-specific autofluorescence quenching protocols:

  • Sudan Black B (0.1-0.3%) treatment for lipofuscin-rich tissues

  • Sodium borohydride treatment (1mg/ml, fresh solution) for aldehyde-induced fluorescence

  • Commercial autofluorescence quenching reagents for challenging samples

• Blocking optimization: Test dual blocking strategy with initial protein block followed by serum block matching secondary antibody host species.

• Antibody dilution optimization: Test SACM1L antibody at higher dilutions than recommended (1:200-1:1000) when using sensitive detection systems.

• Washing stringency: Increase wash duration and volume while maintaining gentle agitation to remove unbound antibodies effectively .

How can researchers validate SACM1L knockdown experiments using antibody-based detection methods?

Rigorous validation of SACM1L knockdown requires multi-faceted antibody-based detection strategies:

• Quantitative Western blot analysis:

  • Load equal protein amounts from control and knockdown samples (confirmed by housekeeping protein detection)

  • Perform densitometric analysis normalized to loading controls

  • Calculate knockdown efficiency as percentage reduction relative to control

  • Expect 60-90% protein reduction with effective siRNA/shRNA approaches

• Immunofluorescence validation:

  • Perform side-by-side staining of control and knockdown cultures under identical conditions

  • Quantify fluorescence intensity across multiple fields using standardized exposure settings

  • Report mean intensity reduction with statistical analysis

• Functional assay correlation:

  • Correlate SACM1L protein reduction with expected cellular phenotypes

  • Monitor phosphoinositide levels using phospholipid-specific probes

  • Assess impact on phosphoinositide-dependent cellular processes

• Timing considerations:

  • Monitor protein reduction over multiple timepoints post-knockdown

  • Account for SACM1L protein half-life when interpreting knockdown efficiency .

How does SACM1L phosphatase activity in 'cis' versus 'trans' configurations impact experimental design and interpretation?

The distinctive catalytic behavior of SACM1L in 'cis' versus 'trans' configurations presents important considerations for experimental design. SACM1L demonstrates robust phosphatase activity when binding PtdIns(4)P in 'cis' configuration within the cellular environment, while exhibiting significantly reduced activity in 'trans' configuration. This configuration-dependent activity is critically important when designing phosphoinositide metabolism studies.

For in vitro enzymatic assays, researchers should consider membrane presentation formats that mimic physiological 'cis' configurations to avoid underestimating SACM1L activity. When utilizing overexpression systems, researchers must account for potential non-physiological 'trans' interactions that may alter apparent enzymatic efficiency. The interaction with regulatory proteins like PLEKHA3, which enhances SACM1L activity in 'trans' configuration, introduces additional complexity requiring careful experimental controls.

Researchers investigating SACM1L inhibitors or activators should evaluate compounds under both 'cis' and 'trans' configurations to comprehensively characterize biological relevance. This configuration-dependent activity fundamentally impacts interpretation of SACM1L's role in cellular phosphoinositide homeostasis .

What are the methodological considerations for using SACM1L antibodies in proximity ligation assays to investigate protein-protein interactions?

Proximity Ligation Assay (PLA) offers powerful capabilities for investigating SACM1L protein interactions, but requires specific methodological considerations:

• Antibody compatibility assessment: SACM1L antibodies must be tested for PLA compatibility, as not all immunofluorescence-validated antibodies perform equivalently in PLA applications due to differences in epitope accessibility when oligonucleotide-conjugated secondary antibodies are employed.

• Negative interaction controls: Beyond standard secondary-only controls, researchers should include biologically relevant negative interaction pairs (proteins known not to interact with SACM1L) to establish background PLA signal thresholds.

• Optimization for SACM1L subcellular localization: As SACM1L localizes to the endoplasmic reticulum and Golgi, specialized fixation and permeabilization protocols may be required:

  • Brief paraformaldehyde fixation (2-3%, 10 minutes) followed by saponin permeabilization (0.1%)

  • Modified blocking with addition of 0.1% Triton X-100 to enhance organelle access

• Proximity threshold calibration: Given SACM1L's membrane association, researchers should calibrate PLA signal interpretation against known interaction partners with defined spatial relationships to accurately interpret novel interaction results.

• Quantification methodology: Automated image analysis workflows specific to membranous compartments rather than whole-cell or nuclear regions should be implemented for accurate quantification of SACM1L interaction puncta .

How can researchers develop immunoassays to detect post-translational modifications of SACM1L protein?

Developing immunoassays for SACM1L post-translational modifications requires careful methodological planning:

• Modification-specific antibody validation strategy:

  • Treat samples with phosphatases, deubiquitinases, or other modification-removing enzymes as negative controls

  • Use stimulation conditions known to induce specific modifications as positive controls

  • Implement peptide competition with modified versus unmodified peptides to confirm specificity

• Sample preparation optimization:

  • Include specific modification-preserving inhibitors in lysis buffers (phosphatase inhibitors, deubiquitinase inhibitors)

  • Optimize gentle lysis conditions to preserve native protein state

  • Consider crosslinking approaches to stabilize transient modifications

• Enrichment strategies:

  • Implement sequential immunoprecipitation: first with total SACM1L antibody, then with modification-specific antibody

  • Consider SACM1L-targeted affinity purification followed by modification-specific Western blotting

  • For phosphorylation studies, employ phospho-enrichment methods prior to SACM1L detection

• Detection method selection:

  • Utilize sandwich ELISA format with capture by total SACM1L antibody and detection with modification-specific antibody

  • Consider proximity-based assays (TR-FRET, HTRF) for enhanced sensitivity to specific modifications

  • Implement multiple reaction monitoring mass spectrometry as orthogonal validation approach .

What methodological advances are enhancing SACM1L research capabilities?

Recent methodological advances have significantly expanded the research toolkit for SACM1L investigations. The development of recombinant monoclonal antibodies has increased reproducibility and reduced batch-to-batch variability compared to traditional hybridoma-derived antibodies. These recombinant antibodies demonstrate enhanced specificity with reduced background staining, as evidenced by comparative studies showing recombinant versions exhibiting moderately higher sensitivity and substantially lower non-specific binding compared to traditional monoclonal antibodies .

Super-resolution microscopy techniques, when combined with highly specific SACM1L antibodies, now enable unprecedented visualization of SACM1L localization within membrane subdomains. This capability is particularly valuable for investigating SACM1L's spatial relationship with phosphoinositide pools and interaction partners.

The integration of antibody-based proximity labeling approaches (BioID, APEX) with SACM1L-specific antibodies for validation has opened new avenues for characterizing the SACM1L interactome under various physiological and pathological conditions. These methodological advances collectively enhance researchers' ability to investigate SACM1L's complex roles in cellular phosphoinositide regulation .

How can researchers effectively combine genetic and antibody-based approaches to elucidate SACM1L function?

A comprehensive investigation of SACM1L function benefits from integrating genetic manipulation with antibody-based detection through these methodological approaches:

• Complementary knockdown/knockout validation:

  • Confirm specificity of antibody-detected phenotypes through correlation with genetic depletion effects

  • Rescue experiments with wild-type versus mutant SACM1L constructs to define structure-function relationships

  • Domain-specific deletions validated by domain-specific antibodies to map functional regions

• CRISPR-Cas9 endogenous tagging:

  • Engineer epitope tags into endogenous SACM1L loci to enable antibody detection without overexpression artifacts

  • Validate tag-specific antibody detection against unmodified cells with SACM1L-specific antibodies

  • Implement dual-detection strategies using both tag antibodies and SACM1L-specific antibodies

• Synthetic genetic interaction screening:

  • Combine SACM1L genetic perturbations with candidate interactor knockdowns

  • Validate genetic interactions using antibody-based co-localization or proximity assays

  • Correlate interaction phenotypes with biochemical interaction strength

• Structure-function studies:

  • Generate point mutations in catalytic domains and regulatory regions

  • Utilize SACM1L antibodies to confirm expression levels of mutant proteins

  • Combine with phosphoinositide-specific probes to correlate structural changes with functional outcomes .